Joshi, MaansiTaper, JForsyth, CecilyRowlings, PhilipCampbell, PhilipCrispin, PhilipHarvey, MichaelUnderhill, CraigBayley, AngelaByth, KarenHuang, Gillian2023-01-121042-8194http://hdl.handle.net/1885/282718Patients with relapsed-refractory diffuse large B-cell lymphoma (RR-DLBCL) ineligible for autologous stem cell transplantation (autoSCT) have poor survival. Thirty transplant-ineligible patients older than 60 years were administered rituximab 375 mg/m2 day 1, ifosfamide 1333 mg/m2 days 1 to 3, and etoposide 80 mg/m2 days 1 to 3 (R-IE) every 21 days for 6 cycles plus 2 doses of rituximab. Revised international prognostic index 3–4 was seen in 53% and prior rituximab exposure in 60%. The complete and overall response rates were 55% and 76%, respectively. Median progression free survival (PFS) and overall survival were 23 and 24 months, respectively. Patients relapsing within 12 months of prior treatment had a median PFS of 2.5 months compared to 23 months for those relapsing beyond 12 months. Grade 3–4 thrombocytopenia and neutropenia occurred in one and eight patients, respectively. R-IE is an effective, well tolerated regimen in RR-DLBCL patients not fit for autoSCT.This study was supported by Roche Products Pty Limited and Amgen Pty Limited. This study was also supported by Amgen Australia Pty Ltd.application/pdfen-AU© 2019 Informa UK Limited, trading as Taylor & Francis GroupLarge cell lymphomarelapsedrefractory202010.1080/10428194.2019.16609682021-11-28